|
1
|
Lafaro KJ, Demirjian AN and Pawlik TM:
Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am.
24:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kulik LM and Chokechanachaisakul A:
Evaluation and management of hepatocellular carcinoma. Clin Liver
Dis. 19:23–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hui D, Qiang L, Jian W, Ti Z and Da-Lu K:
A randomized, controlled trial of postoperative adjuvant
cytokine-induced killer cells immunotherapy after radical resection
of hepatocellular carcinoma. Dig Liver Dis. 41:36–41. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wirth TC: Spontaneous and therapeutic
immune responses in hepatocellular carcinoma: Implications for
current and future immunotherapies. Expert Rev Gastroenterol
Hepatol. 8:101–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Breous E and Thimme R: Potential of
immunotherapy for hepatocellular carcinoma. J Hepatol. 54:830–834.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Unitt E, Marshall A, Gelson W, Rushbrook
SM, Davies S, Vowler SL, Morris LS, Coleman N and Alexander GJ:
Tumour lymphocytic infiltrate and recurrence of hepatocellular
carcinoma following liver transplantation. J Hepatol. 45:246–253.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flecken T, Schmidt N, Hild S, Gostick E,
Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, et
al: Immunodominance and functional alterations of tumor-associated
antigen specific CD8+ T-cell responses in hepatocellular carcinoma.
Hepatology. 59:1415–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang HG, Chen HS, Peng JR, Shang XY,
Zhang J, Xing Q, Pang XW, Qin LL, Fei R, Mei MH, et al: Specific
CD8(+) T cell responses to HLA-A2 restricted MAGE-A3 p271-279
peptide in hepatocellular carcinoma patients without vaccination.
Cancer Immunol Immunother. 56:1945–1954. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Daley S, Evdokimova VN, Zdobinski
DD, Potter DM and Butterfield LH: Hierarchy of alpha fetoprotein
(AFP)-specific T cell responses in subjects with AFP-positive
hepatocellular cancer. J Immunol. 177:712–721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Korangy F, Ormandy LA, Bleck JS,
Klempnauer J, Wilkens L, Manns MP and Greten TF: Spontaneous
tumor-specific humoral and cellular immune responses to NY-ESO-1 in
hepatocellular carcinoma. Clin Cancer Res. 10:4332–4341. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao F, Korangy F and Greten TF: Cellular
immune suppressor mechanisms in patients with hepatocellular
carcinoma. Dig Dis. 30:477–482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Unitt E, Rushbrook SM, Marshall A, Davies
S, Gibbs P, Morris LS, Coleman N and Alexander GJ: Compromised
lymphocytes infiltrate hepatocellular carcinoma: The role of
T-regulatory cells. Hepatology. 41:722–730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hoechst B, Ormandy LA, Ballmaier M, Lehner
F, Krüger C, Manns MP, Greten TF and Korangy F: A new population of
myeloid-derived suppressor cells in hepatocellular carcinoma
patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology.
135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shirabe K, Mano Y, Muto J, Matono R,
Motomura T, Toshima T, Takeishi K, Uchiyama H, Yoshizumi T,
Taketomi A, et al: Role of tumor-associated macrophages in the
progression of hepatocellular carcinoma. Surg Today. 42:1–7. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han YM, Chen ZB, Yang Y, Jiang Z, Gu Y,
Liu Y, Lin C, Pan Z, Yu Y, Jiang M, et al: Human CD14+CTLA-4+
regulatory dendritic cells suppress T-cell response by cytotoxic
T-Lymphocyte antigen-4-dependent IL-10 and
indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Hepatology. 59:567–579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ormandy LA, Hillemann T, Wedemeyer H,
Manns MP, Greten TF and Korangy F: Increased populations of
regulatory T cells in peripheral blood of patients with
hepatocellular carcinoma. Cancer Res. 65:2457–2464. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang XH, Yamagiwa S, Ichida T, Matsuda Y,
Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA and Aoyagi Y:
Increase of CD4+CD25+ regulatory T-cells in the liver of patients
with hepatocellular carcinoma. J Hepatol. 45:254–262. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fu J, Xu DP, Liu Z, Shi M, Zhao P, Fu B,
Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T
cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY,
Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of
regulatory and cytotoxic T cells is associated with prognosis of
hepatocellular carcinoma after resection. J Clin Oncol.
25:2586–2593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moreira-Teixeira L, Resende M, Devergne O,
Herbeuval JP, Hermine O, Schneider E, Dy M, Cordeiro-da-Silva A and
Leite-de-Moraes MC: Rapamycin combined with TGF-β converts human
invariant NKT cells into suppressive Foxp3+ regulatory cells. J
Immunol. 188:624–631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Monteiro M, Almeida CF, Caridade M, Ribot
JC, Duarte J, Agua-Doce A, Wollenberg I, Silva-Santos B and Graca
L: Identification of regulatory Foxp3+ invariant NKT cells induced
by TGF-beta. J Immunol. 185:2157–2163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH
and Wang RF: Tumor infiltrating gammadelta T cells suppress T and
dendritic cell function via mechanisms controlled by a unique
Toll-like receptor signaling pathway. Immunity. 27:334–348. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pang YL, Zhang HG, Peng JR, Pang XW, Yu S,
Xing Q, Yu X, Gong L, Yin YH, Zhang Y and Chen WF: The
immunosuppressive tumor microenvironment in hepatocellular
carcinoma. Cancer Immunol Immunother. 58:877–886. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Norris S, Collins C, Doherty DG, Smith F,
McEntee G, Traynor O, Nolan N, Hegarty J and O'Farrelly C: Resident
human hepatic lymphocytes are phenotypically different from
circulating lymphocytes. J Hepatol. 28:84–90. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Doherty DG and O'Farrelly C: Innate and
adaptive lymphoid cells in the human liver. Immunol Rev. 174:5–20.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Doherty DG, Norris S, Madrigal-Estebas L,
McEntee G, Traynor O, Hegarty JE and O'Farrelly C: The human liver
contains multiple populations of NK cells, T cells, and CD3+CD56+
natural T cells with distinct cytotoxic activities and Th1, Th2,
and Th0 cytokine secretion patterns. J Immunol. 163:2314–2321.
1999.PubMed/NCBI
|
|
27
|
Norris S, Doherty DG, Collins C, McEntee
G, Traynor O, Hegarty JE and O'Farrelly C: Natural T cells in the
human liver: Cytotoxic lymphocytes with dual T cell and natural
killer cell phenotype and function are phenotypically heterogenous
and include Valpha24-JalphaQ and gammadelta T cell receptor bearing
cells. Hum Immunol. 60:20–31. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kawarabayashi N, Seki S, Hatsuse K, Ohkawa
T, Koike Y, Aihara T, Habu Y, Nakagawa R, Ami K, Hiraide H and
Mochizuki H: Decrease of CD56(+) T Cells and natural killer cells
in cirrhotic livers with hepatitis C may be involved in their
susceptibility to hepatocellular carcinoma. Hepatology. 32:962–969.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Golden-Mason L, Castelblanco N, O'Farrelly
C and Rosen HR: Phenotypic and functional changes of cytotoxic
CD56pos natural T cells determine outcome of acute hepatitis C
virus infection. J Virol. 81:9292–9298. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye L, Wang X, Wang S, Wang Y, Song L, Hou
W, Zhou L, Li H and Ho W: CD56+ T cells inhibit hepatitis C virus
replication in human hepatocytes. Hepatology. 49:753–762. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gulubova M, Manolova I, Kyurkchiev D,
Julianov A and Altunkova I: Decrease in intrahepatic CD56+
lymphocytes in gastric and colorectal cancer patients with liver
metastases. APMIS. 117:870–879. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Doskali M, Tanaka Y, Ohira M, Ishiyama K,
Tashiro H, Chayama K and Ohdan H: Possibility of adoptive
immunotherapy with peripheral blood-derived CD3-CD56+ and CD3+CD56+
cells for inducing antihepatocellular carcinoma and antihepatitis C
virus activity. J Immunother. 34:129–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao Y, Wang B, Huang ZL, Shi M, Yu XJ,
Zheng L, Li S and Li L: Increased circulating Th17 cells after
transarterial chemoembolization correlate with improved survival in
stage III hepatocellular carcinoma: A prospective study. PLoS One.
8:e604442013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cai L, Zhang Z, Zhou L, Wang H, Fu J,
Zhang S, Shi M, Zhang H, Yang Y, Wu H, et al: Functional impairment
in circulating and intrahepatic NK cells and relative mechanism in
hepatocellular carcinoma patients. Clin Immunol. 129:428–437. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakajima T, Mizushima N and Kanai K:
Relationship between natural killer activity and development of
hepatocellular carcinoma in patients with cirrhosis of the liver.
Jpn J Clin Oncol. 17:327–332. 1987.PubMed/NCBI
|
|
36
|
Kiniwa Y, Miyahara Y, Wang HY, Peng W,
Peng G, Wheeler TM, Thompson TC, Old LJ and Wang RF: CD8+Foxp3+
regulatory T cells mediate immunosuppression in prostate cancer.
Clin Cancer Res. 13:6947–6958. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH
and Wang RF: Tumor-infiltrating gammadelta T cells suppress T and
dendritic cell function via mechanisms controlled by a unique
toll-like receptor signaling pathway. Immunity. 27:334–348. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cao X, Cai SF, Fehniger TA, Song J,
Collins LI, Piwnica-Worms DR and Ley TJ: Granzyme B and perforin
are important for regulatory T cell-mediated suppression of tumor
clearance. Immunity. 27:635–646. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gavin MA, Rasmussen JP, Fontenot JD, Vasta
V, Manganiello VC, Beavo JA and Rudensky AY: Foxp3-dependent
programme of regulatory T-cell differentiation. Nature.
445:771–775. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fontenot JD, Gavin MA and Rudensky AY:
Pillars Article: Foxp3 programs the development and function of
CD4+CD25+ regulatory T cells. Nat Immunol 2003. 4: 330–336. J
Immunol. 198:986–992. 2017.PubMed/NCBI
|
|
41
|
Hori S, Nomura T and Sakaguchi S: Pillars
Article: Control of regulatory T cell development by the
transcription factor Foxp3. Science 2003. 299: 1057–1061. Science.
198:981–985. 2017.
|
|
42
|
Kim JY, Kim HJ, Hurt EM, Chen X, Howard OM
and Farrar WL: Functional and genomic analyses of FOXP3-transduced
Jurkat-T cells as regulatory T (Treg)-like cells. Biochem Biophys
Res Commun. 362:44–50. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ziegler SF: FOXP3: Of mice and men. Annu
Rev Immunol. 24:209–226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yaqi H, Nomura T, Nakamura K, Yamazaki S,
Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S and
Sakaguchi S: Crucial role of FOXP3 in the development and function
of human CD25+CD4+ regulatory T cells. Int Immunol. 16:1643–1656.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Allan SE, Alstad AN, Merindol N, Crellin
NK, Amendola M, Bacchetta R, Naldini L, Roncarolo MG, Soudeyns H
and Levings MK: Generation of potent and stable human CD4+ T
regulatory cells by activation-independent expression of FOXP3. Mol
Ther. 16:194–202. 2008. View Article : Google Scholar : PubMed/NCBI
|
